Recent Lung Cancer - Non-Small Cell News

November Is National Lung Cancer Awareness Month

(October 23, 2018)

Treatment advances – lung cancer resources and advocacy are making the difference The month of November brings lung cancer into focus. Over the past few years great strides have been made in the... Continue Reading


Blood Test Identifies More Treatable Cancer Mutations Than Tissue Biopsy Alone

(October 15, 2018)

Penn study shows patients with treatable mutations identified by liquid biopsy also largely respond to therapy October 11, 2018 PHILADELPHIA – In one of the largest clinical studies to ever examine... Continue Reading


Overall Health, Not Just Age, is an Important Factor in Treatment of Non-Small Cell Lung Cancer

(July 10, 2018)

Two clinical studies highlight the importance of evaluating overall health instead of age in the management of lung cancer. In fact, younger patients with non-small cell lung cancer (NSCLC) are more likely... Continue Reading


Xalkori Receives FDA Breakthrough Therapy Designation for Treatment of Lung Cancer with MET Alterations

(June 5, 2018)

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for Xalkori (crizotinib) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with MET exon... Continue Reading


Overall Health, Not Just Age, is an Important Factor in Treatment of Non-Small Cell Lung Cancer

(April 11, 2018)

Younger patients with non-small cell lung cancer (NSCLC) are more likely to receive treatment than older patients, regardless of overall health and prognosis, according to the results of a study published... Continue Reading


FDA Broadens Gilotrif Indication to Previously Untreated, Metastatic NSCLC with Other Non-Resistant EGFR Mutations

(January 24, 2018)

CancerConnect News: The Food and Drug Administration (FDA) has granted approval to Gilotrif®  (afatinib) for a broadened indication in first-line treatment of patients with metastatic non-small cell... Continue Reading


Keytruda in Combination with Alimta and Platinum Chemotherapy Improves Survival in Non Small Cell Lung Cancer

(January 17, 2018)

CancerConnect News: Keytruda (pembrolizumab) is the first PD1 Inhibitor to demonstrate improved overall survival when combined with chemotherapy as primary treatment for metastatic non-squamous non-small... Continue Reading


First Line Combination Therapy Improves Progression-Free Survival In Advanced Lung Cancer

(January 8, 2018)

A recently reported study confirms that combination therapy using the “checkpoint inhibitor” Tecentriq® (atezolizumab) and chemotherapy as first line treatment for advanced non-squamous non-small-cell... Continue Reading


The Role of Immunotherapy in the Treatment of Advanced Non Small Cell Lung Cancer

(December 6, 2017)

Treatment options for advanced NSCLC fit into 3 main categories… Targeted Therapy – we test lung cancer for specific mutations to see if we have an appropriate targeted medication. Immunotherapy –... Continue Reading


Alcensa Precision Medicine Approved for (ALK) Positive Non-Small Cell Lung Cancer

(November 13, 2017)

The Food and Drug Administration granted regular approval to Alcensa (alectinib), for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC),... Continue Reading


Next Page »